Hepatitis C Vaccines, Antibodies, and T Cells

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Jul 14

PMID 30002657

Citations 36

Authors

Naglaa H Shoukry

Affiliations

Soon will be listed here.

Abstract

The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.

Citing Articles

Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodies.

Nagarathinam K, Scheck A, Labuhn M, Stroh L, Herold E, Veselkova B Sci Adv. 2024; 10(49):eado2600.

PMID: 39642219 PMC: 11623273. DOI: 10.1126/sciadv.ado2600.

Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virus.

Czarnota A, Raszplewicz A, Slawinska A, Bienkowska-Szewczyk K, Grzyb K Sci Rep. 2024; 14(1):26698.

PMID: 39496832 PMC: 11535267. DOI: 10.1038/s41598-024-78049-3.

Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report.

Morihisa Y, Chung H, Towatari S, Yamashita D, Inokuma T World J Hepatol. 2024; 16(2):286-293.

PMID: 38495284 PMC: 10941733. DOI: 10.4254/wjh.v16.i2.286.

Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine.

Tabll A, Sohrab S, Ali A, Petrovic A, Steiner Srdarevic S, Siber S Pathogens. 2024; 13(1).

PMID: 38251345 PMC: 10820710. DOI: 10.3390/pathogens13010038.

Chronic HCV infection promotes cytotoxicity in antigen-specific CD8 T cells regardless of virus specificity.

Maretti-Mira A, Salomon M, Hsu A, Matsuba C, Golden-Mason L Front Virol. 2023; 3.

PMID: 37886042 PMC: 10601542. DOI: 10.3389/fviro.2023.1198361.

References

Paley M, Kroy D, Odorizzi P, Johnnidis J, Dolfi D, Barnett B . Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012; 338(6111):1220-5. PMC: 3653769. DOI: 10.1126/science.1229620. View

Maher L, White B, Hellard M, Madden A, Prins M, Kerr T . Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine. 2010; 28(45):7273-8. PMC: 3729933. DOI: 10.1016/j.vaccine.2010.08.085. View

Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder J . The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000; 288(5464):339-44. DOI: 10.1126/science.288.5464.339. View

Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P . Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191(9):1499-512. PMC: 2213430. DOI: 10.1084/jem.191.9.1499. View

Falade-Nwulia O, Sulkowski M, Merkow A, Latkin C, Mehta S . Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018; 25(3):220-227. PMC: 5841922. DOI: 10.1111/jvh.12859. View

Dorner M, Horwitz J, Robbins J, Barry W, Feng Q, Mu K . A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011; 474(7350):208-11. PMC: 3159410. DOI: 10.1038/nature10168. View

Netski D, Mosbruger T, Depla E, Maertens G, Ray S, Hamilton R . Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005; 41(5):667-75. DOI: 10.1086/432478. View

Wong J, Bhat R, Hockman D, Logan M, Chen C, Levin A . Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol. 2014; 88(24):14278-88. PMC: 4249152. DOI: 10.1128/JVI.01911-14. View

Radziewicz H, Ibegbu C, Fernandez M, Workowski K, Obideen K, Wehbi M . Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol. 2006; 81(6):2545-53. PMC: 1865979. DOI: 10.1128/JVI.02021-06. View

10.

Pawlotsky J, Feld J, Zeuzem S, Hoofnagle J . From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62(1 Suppl):S87-99. DOI: 10.1016/j.jhep.2015.02.006. View

11.

Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A . Animal models for hepatitis C. Curr Top Microbiol Immunol. 2013; 369:49-86. DOI: 10.1007/978-3-642-27340-7_3. View

12.

Mehta S, Cox A, Hoover D, Wang X, Mao Q, Ray S . Protection against persistence of hepatitis C. Lancet. 2002; 359(9316):1478-83. DOI: 10.1016/S0140-6736(02)08435-0. View

13.

Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A . Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996; 93(26):15394-9. PMC: 26415. DOI: 10.1073/pnas.93.26.15394. View

14.

Pestka J, Zeisel M, Blaser E, Schurmann P, Bartosch B, Cosset F . Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007; 104(14):6025-30. PMC: 1851610. DOI: 10.1073/pnas.0607026104. View

15.

Gupta P, Godec J, Wolski D, Adland E, Yates K, Pauken K . CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog. 2015; 11(10):e1005177. PMC: 4618999. DOI: 10.1371/journal.ppat.1005177. View

16.

Law J, Chen C, Wong J, Hockman D, Santer D, Frey S . A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One. 2013; 8(3):e59776. PMC: 3602185. DOI: 10.1371/journal.pone.0059776. View

17.

Capone S, Naddeo M, DAlise A, Abbate A, Grazioli F, Del Gaudio A . Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. Mol Ther. 2014; 22(5):1039-47. PMC: 4015230. DOI: 10.1038/mt.2014.15. View

18.

Dowd K, Netski D, Wang X, Cox A, Ray S . Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology. 2009; 136(7):2377-86. PMC: 2895772. DOI: 10.1053/j.gastro.2009.02.080. View

19.

Frey S, Houghton M, Coates S, Abrignani S, Chien D, Rosa D . Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010; 28(38):6367-73. PMC: 2923449. DOI: 10.1016/j.vaccine.2010.06.084. View

20.

Smith D, Bukh J, Kuiken C, Muerhoff A, Rice C, Stapleton J . Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2013; 59(1):318-27. PMC: 4063340. DOI: 10.1002/hep.26744. View